CEL-SCI Corporation (NYSEAMERICAN: CVM) will schedule an AGM at 10 AM on July 1, 2021. It will also discuss head and neck cancer phase 3 clinical study results after the AGM on the same day.
After conducting a shareholder conference for 10 minutes, Eyal Talor, CEL-SCI’s CEO, will present a head and neck cancer Phase 3 clinical trial.
Multikine showed a significant 5-year survival benefit of 14.1% in phase 3 clinical studies in patients who underwent surgery and radiotherapy. As a result, CEL-SCI plans to submit an application with the US FDA seeking approval for this patient group.
What is Multikine?
Investigational cancer immunotherapy – Multikine expects to contain fourteen natural human cytokines such as chemokines, interferons, interleukins, and colony-stimulating factors.
Human cytokines protect humans against cancer and other related diseases. CEL-SCI mass produces Multikine using its proprietary process adhering to GMP.
The company is conducting clinical trials to ascertain its safety and efficacy profiles.
An alert to shareholders
The prominent law firms – Pomerantz LLP and Gewirtz & Grossman, LLC are probing CEL-SCI on behalf of shareholders to determine whether the company, its directors, and officers are involved in unlawful business practices or securities fraud.
CEL-SCI released a press note on June 28, 2021, announcing the phase 3 clinical trials of its leukocyte interleukin (Multikine) immunotherapy candidate failed to meet the primary objective of previously untreated squamous cell carcinoma in the head and neck. As a result of this news, its share price declined by 45.41%, or $11.39/share, and settled at $13.69/share on June 28, 2021.
Investors can approach Pomerantz LLP or Gewirtz & Grossman, LLC to get the additional information and submit a claim for the losses caused because of unlawful activities of CEL-SCI and its directors/ officers.
CEL-SCI utilizes T-Cell modulation, patented and peptide epitope delivery technology – Ligand Epitope Antigen Presentation System – LEAPS to design and synthesize peptide immunogens.
LEAPS compounds comprise a small T-cell binding peptide ligand associated with a disease. The company showed that this technology could directly respond to a humoral, cellular, or mixed pathway.
CEL-SEI can use LEAPS to develop potential drug candidates to cure autoimmune diseases, cancer, some infectious diseases, allergy, allergic asthma, and some CNS diseases.